Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.
Ranee Mehra(University of Maryland, Baltimore), Robert I. Haddad(Georgetown University), Tanguy Y. Seiwert(Georgetown University), Makoto Tahara(National Cancer Center Hospital East), Dung T. Le(Johns Hopkins University), Barbara Burtness(Yale University), Amy Meister(Georgetown University), Chia‐Chi Lin(National Taiwan University Hospital), Joseph P. Eder(Yale Cancer Center), Ravit Geva(Tel Aviv Sourasky Medical Center), Raanan Berger(Tel Aviv University), Laura Q.M. Chow(The University of Texas at Austin), Kei Muro(Aichi Cancer Center), Bhumsuk Keam(Seoul National University Hospital), Hyun Cheol Chung(Yonsei University), Jared Weiss(Georgetown University), Darcy A. Hille(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan D. Cheng(Princeton University), Amit Mahipal(Dana-Farber Cancer Institute)
Cited by 45
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k